Eton Pharmaceuticals (NASDAQ:ETON) Insider Ipek Erdogan-Trinkaus Sells 3,500 Shares of Company Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider Ipek Erdogan-Trinkaus sold 3,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $67.41, for a total transaction of $235,935.00. Following the transaction, the insider owned 4,081 shares of the company’s stock, valued at approximately $275,100.21. This represents a 46.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Eton Pharmaceuticals Trading Down 10.2%

ETON traded down $6.95 during mid-day trading on Thursday, hitting $61.45. The stock had a trading volume of 1,015,747 shares, compared to its average volume of 462,978. The stock’s fifty day simple moving average is $55.19 and its 200-day simple moving average is $37.24. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.79 and a quick ratio of 1.58. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 40.70 and a beta of 0.89. Eton Pharmaceuticals, Inc. has a 1-year low of $14.27 and a 1-year high of $70.64.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 104.82%. The company had revenue of $57.93 million for the quarter, compared to analysts’ expectations of $41.98 million. As a group, research analysts forecast that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ETON. Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright raised their price target on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Craig Hallum reiterated a “buy” rating and set a $78.00 price objective on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Canaccord Genuity Group boosted their price objective on Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Finally, Weiss Ratings raised Eton Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Voya Investment Management LLC acquired a new stake in Eton Pharmaceuticals in the 3rd quarter valued at approximately $264,000. Global Retirement Partners LLC acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $26,000. Morse Asset Management Inc acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $35,000. JW Asset Management LLC bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $690,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Eton Pharmaceuticals by 296.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 32,362 shares of the company’s stock worth $1,666,000 after acquiring an additional 24,195 shares in the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.